Targeting metabolic needs in p53 mutant triple-negative breast cancer
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-10847339
This study is looking at how certain breast cancers, especially those with a p53 gene mutation, use specific nutrients to grow, and it’s trying to find a way to block a key enzyme called ASAH1 that helps these cancers survive, which could lead to new treatments for patients with this tough type of breast cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-10847339 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the unique metabolic requirements of triple-negative breast cancers (TNBCs) that have mutations in the p53 gene. By using advanced techniques, the researchers aim to identify specific metabolic enzymes that are crucial for the survival and growth of these cancer cells. They have discovered a key enzyme, ASAH1, which appears to be essential for the tumor-forming ability of p53-mutant TNBCs. The study also explores small molecule inhibitors that can effectively target ASAH1, potentially leading to new treatment options for patients with this aggressive form of breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer that has a p53 mutation.
Not a fit: Patients with non-triple-negative breast cancer or those without p53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies specifically for patients with p53-mutant triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUPTA, ROMI — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: GUPTA, ROMI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer